Jeff Evans has been editor of Rheumatology News/MDedge Rheumatology and the EULAR Congress News since 2013. He started at Frontline Medical Communications in 2001 and was a reporter for 8 years before serving as editor of Clinical Neurology News and World Neurology, and briefly as editor of GI & Hepatology News. He graduated cum laude from Cornell University (New York) with a BA in biological sciences, concentrating in neurobiology and behavior.
News
Rheumatology workforce shortage demands multipronged approach
Members of the American College of Rheumatology’s Workforce Solutions Committee described a multitude of ways in which the society aims to marshal...
News
Intensive gout treatment meets urate goal, lowers tophi burden
A randomized trial of therapy to intensively lower urate for patients with gout showed benefits in meeting serum urate goal, tophus size, and...
News
FDA approves upadacitinib (Rinvoq) for sixth indication
Upadacitinib’s approval for nonradiographic axial spondyloarthritis marks the sixth indication in the United States for the Janus kinase inhibitor...
News
Analysis of PsA guidelines reveals much room for improvement on conflicts of interest
Researchers show that a majority of the authors of the most recent psoriatic arthritis clinical practice guidelines from the American College of...
News
FDA approves adalimumab-bwwd biosimilar (Hadlima) in high-concentration form
The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.
News
Ustekinumab becomes second biologic approved for PsA in kids
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to...
News
Rheumatology awards from ACR, EULAR, and BSR reveal gender gap
The number of female prize winners has increased over the past 2 decades to nearly equal that of male winners, but the most prestigious prizes are...
News
Upadacitinib recommended for nonradiographic axSpA in Europe
The Janus kinase inhibitor is already approved for active ankylosing spondylitis in the European Union.
News
Osteoporosis risk rises with air pollution levels
Chronic exposure to particulate matter 2.5 mcm or larger in size at concentrations above 25 mcg per cubic meter raised the likelihood of...
News
FDA adds RA indication for Riabni rituximab biosimilar
Riabni is the second rituximab biosimilar to be approved for rheumatoid arthritis in the United States.
News
Secukinumab’s antipsoriatic effects confirmed in U.S. patient population
Results from a postmarketing trial conducted solely at U.S. centers found similar, albeit lower, responses to secukinumab 300 mg than was noted in...
News
Orphenadrine recalled due to possible nitrosamine impurity
The voluntary recall of Orphenadrine Citrate 100 mg Extended Release Tablets by Sandoz involves 13 lots of the drug that were shipped to consumers...
News
Rheumatologist convicted of fraudulently billing millions of dollars in services
Alice Chu, MD, is 1 of 48 people who were charged in 2019 as part of a larger enforcement action involving more...
News
Rheumatology News celebrates 20 years
Rheumatology News’ first issue was published in February 2002, and in 2022 we’ll be taking a look back at rheumatology’s past and ahead to its...
News
Lilly calls it quits on baricitinib’s development for lupus
The company said it is stopping phase 3 trials because of disappointing results.